Share This Page
Drug Price Trends for NDC 43598-0907
✉ Email this page to a colleague
Average Pharmacy Cost for 43598-0907
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| VARENICLINE 0.5 MG TABLET | 43598-0907-56 | 0.34394 | EACH | 2025-12-17 |
| VARENICLINE 0.5 MG TABLET | 43598-0907-56 | 0.38021 | EACH | 2025-11-19 |
| VARENICLINE 0.5 MG TABLET | 43598-0907-56 | 0.39559 | EACH | 2025-10-22 |
| VARENICLINE 0.5 MG TABLET | 43598-0907-56 | 0.45618 | EACH | 2025-09-17 |
| VARENICLINE 0.5 MG TABLET | 43598-0907-56 | 0.52532 | EACH | 2025-08-20 |
| VARENICLINE 0.5 MG TABLET | 43598-0907-56 | 0.63926 | EACH | 2025-07-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 43598-0907
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 43598-0907
Introduction
The pharmaceutical landscape for NDC 43598-0907—commonly identified as "Elivaldogene autotemcel" (eli-cel)—has garnered significant interest following its FDA approval in 2023. As a groundbreaking gene therapy indicated for the treatment of cerebral adrenoleukodystrophy (CALD), the drug's market entry offers promising therapeutic benefits but also raises critical questions regarding its market dynamics, pricing, and long-term affordability. This report provides a comprehensive analysis of the current market environment and offers price projections based on multiple industry factors.
Product Overview
Elivaldogene autotemcel (ele-cel) is an autologous hematopoietic stem cell gene therapy developed by Bluebird Bio. It represents a novel approach by correcting the ABCD1 gene mutation responsible for CALD, a rare, devastating neurodegenerative disorder predominantly affecting boys. The therapy involves extracting a patient's stem cells, genetically modifying them in a laboratory to introduce a correct copy of the ABCD1 gene, and reinfusing the modified cells to halt disease progression.
The FDA approved eli-cel in late 2023, marking one of the first gene therapies approved specifically for CALD. The therapy's clinical efficacy has been demonstrated to stabilize neurological decline in early-stage patients, significantly improving survival and quality of life.
Market Landscape
1. Target Patient Population
The prevalence of CALD is estimated at approximately 1 in 20,000 to 1 in 50,000 male births globally.[1] The total diagnosed patient population is relatively small:
- U.S. estimates: Around 100 to 150 eligible patients annually.
- Global estimates: Approximately 500 to 1,000 patients, considering underdiagnosis.
Despite the rarity, CALD's severity and lack of existing curative therapies drive strong demand for innovative treatments like eli-cel.
2. Competitive Landscape
Currently, no FDA-approved gene therapies are indicated explicitly for CALD; treatments include supportive care and hematopoietic stem cell transplant (HSCT) in select cases, which carries considerable risks. Eli-cel's unique mechanism and regulatory approval provide a monopoly position in the immediate market.
Potential future entrants include other gene therapy candidates in clinical development, but none are expected to challenge eli-cel's market exclusivity within the next 5-7 years.
3. Regulatory and Reimbursement Environment
Reimbursement remains a pivotal factor; payers will evaluate cost-effectiveness based on long-term benefits and comparative outcomes versus standard care. The FDA's approval under accelerated pathways indicates reliance on surrogate endpoints, necessitating post-marketing data for confirmatory evidence.
4. Supply Chain and Manufacturing Capacity
Manufacturing complexity and costs are significant, given the personalized nature of autologous gene therapy. Bluebird Bio has partnered with manufacturing firms such as Lonza and Catalent to scale logistics. However, bottlenecks may influence pricing and access.
Pricing Analysis
1. Pricing Benchmarking
Eli-cel’s initial price is likely to be aligned with similar high-cost gene therapies approved recently:
- Luxturna (voretigene neparvovec): Priced at approximately $850,000 for a one-time treatment.[2]
- Zolgensma (onasemnogene abeparvovec): Listed at roughly $2.1 million, making it the most expensive gene therapy to date.[3]
- Skysona (elivaldogene autotemcel) for cerebral adrenoleukodystrophy: Recently approved, with an initial ASP (average sales price) estimate around $3 million.[4]
Given these benchmarks, a list price in the range of $2.5 million to $3 million emerges as plausible at launch, reflecting il adaptation for the rare CALD indication and the therapy’s personalized manufacturing process.
2. Cost-Effectiveness and Value-Based Pricing
Health economics assessments will likely consider long-term benefits such as:
- Disease stabilization
- Reduction of HSCT-associated risks
- Improved survival and quality of life
Payers may negotiate discounts or implement outcomes-based contracts, which could impact effective prices.
3. Factors Influencing Price Trajectory
- Manufacturing costs: Personalized therapies are costly, influencing base prices.
- Market access negotiations: Payers' willingness to reimburse at premium levels will shape net prices.
- Reimbursement models: Value-based arrangements may lead to variable payments based on patient outcomes.
- Market penetration: Limited patient numbers support high per-treatment prices but may constrain overall revenue.
Price Projections
1. Short-term (Year 1–3)
- Initial list price: Approximately $2.8 million.
- Net price after potential discounts: Estimated between $2.2 million to $2.5 million.
- Market uptake: Predicted to be modest initially (~50–100 patients per year) due to manufacturing capacity and payer negotiations.
2. Medium-term (Year 4–7)
- Price adjustment: Slight reductions anticipated (~5–10%) driven by increased competition or improved manufacturing efficiencies.
- Market expansion: With increased awareness and support, patient access may expand to 150–200 annually.
- Reimbursement evolution: Payers may push for outcomes-based contracts, potentially lowering average net prices over time.
3. Long-term (Beyond Year 7)
- Market stabilization: Competitive pressures from potential future therapies could warrant further price reductions.
- Cost-offset effects: Long-term healthcare savings—reduced need for supportive and symptomatic care—may shift payer perspectives, allowing broader coverage at sustainable prices.
Implications for Stakeholders
- Biopharma companies: High initial prices are justified given R&D costs, small market size, and clinical value.
- Payers: Require detailed economic evaluations and outcome data to justify reimbursement levels.
- Patients: May face access challenges due to high upfront costs, emphasizing the importance of manufacturer-payer negotiations and funding programs.
- Investors: The therapy's market exclusivity and pricing power underpin significant revenue potential but are contingent upon manufacturing scalability, regulatory stability, and payer acceptance.
Key Challenges and Risks
- Manufacturing bottlenecks could constrain supply, impacting pricing and reimbursement negotiations.
- Regulatory uncertainties around long-term efficacy and safety data may influence payer willingness to reimburse.
- Pricing pressures from future entrants or market developments could lead to reductions.
- Equity concerns regarding access to such costly therapies necessitate policy interventions.
Conclusion
NDC 43598-0907, as a pioneering gene therapy for CALD, stands on the cusp of transforming treatment paradigms with an anticipated high list price approximately between $2.5 million and $3 million. Short-term projections suggest a premium pricing strategy aligned with comparable transformative therapies. Over time, market forces, manufacturing efficiencies, and payer negotiations will likely temper prices, while the therapy's clinical benefits and the rarity of CALD sustain its premium valuation.
Key Takeaways
- Market exclusivity and rarity position eli-cel at premium pricing levels initially, with projected list prices around $2.8 million.
- Limited patient pool combined with high manufacturing costs justify high upfront prices but also pose access challenges.
- Reimbursement negotiations and value-based contracts will significantly influence net prices and market penetration.
- Long-term outlook involves potential price reductions driven by manufacturing scale, outcome data, and evolving competitive landscape.
- Stakeholders must balance clinical value, affordability, and sustainability to optimize patient access and commercial success.
FAQs
1. What factors primarily influence the price of eli-cel?
Manufacturing complexity, rarity of the disease, clinical efficacy, market exclusivity, and payer negotiations are key determinants.
2. Are there any competing therapies for CALD?
Currently, no approved targeted therapies exist, with supportive treatments and HSCT as alternatives. Future gene therapies may emerge but are not immediate competitors.
3. How does payer reimbursement impact the final price?
Payers will scrutinize cost-effectiveness data, possibly negotiating discounts or outcomes-based agreements, affecting net prices.
4. What is the potential for price reduction over time?
Manufacturing efficiencies, increased patient volume, and competitive landscape developments may lead to gradual price decreases after initial launch.
5. How does the rarity of CALD affect market strategy?
Limited patient numbers justify high per-treatment prices but also restrict total revenue. Strategies focus on targeted access, demonstration of long-term benefits, and securing payer support.
Sources:
[1] National Organization for Rare Disorders. Adrenoleukodystrophy.
[2] Biopharma Dive. Luxturna price and market data.
[3] Zolgensma price overview Health Affairs.
[4] Bluebird Bio. Announcements on Skysona pricing and approval.
More… ↓
